Gastric adenocarcinoma: Review and considerations for future directions

Annals of Surgery

Volumn 241, Issue 1, 2005, Pages 27-39

  Dicken, Bryan J ^a   Bigam, David L ^a   Cass, Carol ^a   Mackey, John R ^a   Joy, Anil A ^a   Hamilton, Stewart M ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; TAXANE DERIVATIVE;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL PRACTICE; CLINICAL TRIAL; DNA MICROARRAY; GASTRECTOMY; GENE EXPRESSION PROFILING; HUMAN; LYMPHADENECTOMY; MEDICAL DECISION MAKING; MEDICAL LITERATURE; META ANALYSIS; MOLECULAR BIOLOGY; OUTCOMES RESEARCH; PATHOLOGY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SIDE EFFECT; STOMACH ADENOCARCINOMA; SURGICAL TECHNIQUE; SYSTEMATIC REVIEW;

ADENOCARCINOMA; ADULT; AGED; DECISION MAKING; FEMALE; GASTRECTOMY; GENE EXPRESSION PROFILING; HUMANS; LYMPH NODE EXCISION; MALE; MIDDLE AGED; MODELS, STATISTICAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PERITONEAL CAVITY; PREDICTIVE VALUE OF TESTS; RISK FACTORS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 11044225555     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.sla.0000149300.28588.23     Document Type: Review

References (143)

1. Bozzetti F, Marubini E, Bonfanti G, et al. Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Ann Surg. 1999;230:170-178.
2. Borch K, Jonsson B, Tarpila E, et al. Changing patterns of histological type, location, stage, and outcome of surgical treatment of gastric carcinoma. Br J Surg. 2000;87:618-626.
3. Davis P, Takeshi S. The difference in gastric cancer between Japan, USA, and Europe: what are the facts? What are the suggestions? Crit Rev Oncol Hematol. 2001;40:77-94.
4. World Health Organization, Cancer Surveillance Database. Available at: www-dep.iarc.fr.
5. Canadian Cancer Statistics, 2002. Available at: www.hc-sc.gc.ca.
6. Crawford J. The gastrointestinal tract. In: Robbins SLCR, Kumar V, Schoen FJ, eds. Pathologic Basis of Disease. Philadelphia: WB Saunders Co; 1994:755-783.
7. Schwartz G. Invasion and metastasis in gastric cancer: in vitro and in vivo models with clinical considerations. Semin Oncol. 1996;23:316-324.
8. Green D, Ponce de Leon S, Leon-Rodriguez E, et al. Adenocarcinoma of the stomach: univariate and multivariate analysis of factors associated with survival. Am J Oncol. 2002;25:84-89.
9. Msika S, Benhamiche A, Jouve J-L, et al. Prognostic factors after curative resection of gastric cancer. A population-based study. Eur J Cancer. 2000;36:390-396.
10. Harrison L, Karpeh M, Brennan M. Extended lymphadenectomy is associated with a survival benefit for node-negative gastric cancer. J Gastrointest Surg. 1998;2:126-131.
11. Gore R. Gastrointestinal cancer. Radiol Clin North Am. 1997;35:295-310.
12. Karpeh M, Brennan M. Gastric carcinoma. Ann Surg Oncol. 1998;5: 650-656.
13. Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of US gastric carcinoma patients treated with gastrectomy: fifth edition American Joint Committee on Cancer staging, proximal disease, and the 'different disease' hypothesis. Cancer. 2000;88:921-932.
14. MacDonald J, Smalley S, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725-729.
15. Doglietto G, Pacelli F, Caprino P, et al. Surgery: independent prognostic factor in curable and far advanced gastric cancer. World J Surg. 2000;24:459-464.
16. Hartgrink H, Putter H, Kranenbarg E, et al. Value of palliative resection in gastric cancer. Br J Surg. 2002;89:1438-1443.
17. Philip P, Ajani J. Gastric carcinoma. In: Pazdur R, ed. Medical Oncology: A Comprehensive Review, 2nd ed. Houston, TX; 1997.
18. Prankin D, Whelon S, Ferlay J, et al. Cancer Incidence in Five Continents. Lyon, France: IARC Press; 1997.
19. Fenogilo-Preiser C, Carneiro F, Correa P, et al. Gastric carcinoma. In: Hamilton S, Aaltonin L, eds. Pathology and Genetics. Tumors of the Digestive System, vol 1. Lyon, France: Lyon Press; 2000:37-52.
20. Haung X-E, Tajima K, Hamajima N, et al. Effects of dietary, drinking, and smoking habits on the prognosis of gastric cancer. Nutr Cancer. 2000;38:30-36.
21. Ramon JM, Serra L, Cerdo C, et al. Dietary factors and gastric cancer risk. A case-control study in Spain. Cancer. 1993;71:1731-1735.
22. Devisa S, Blot W, Fraumeni J. Changing patterns in the incidence of esophageal and gastric carcinoma in the US. Cancer. 1998;83:2049-2053.
23. La Vecchia C, Negri E, Franceschi S, et al. Family history and the risk of stomach and colorectal cancer. Cancer. 1992;70:50-55.
24. Huntsman DG, Carneiro F, Lewis FR, et al. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med. 2001;344:1904-1909.
25. Ascano JJ, Frierson H Jr, Moskaluk CA, et al. Inactivation of the E-cadherin gene in sporadic diffuse-type gastric cancer. Mod Pathol. 2001;14:942-949.
26. Dussaulx-Garin L, Blayau M, Pagenault M, et al. A new mutation of E-cadherin gene in familial gastric linitis plastica cancer with extra-digestive dissemination. Eur J Gastroenterol Hepatol. 2001;13:711-715.
27. Machado J, Soares P, Carneiro F, et al. E-cadherin gene mutations provide a genetic basis for the phenotypic divergence of mixed gastric carcinomas. Lab Invest. 1999;79:459-465.
28. Faivre J, Benhamiche A. Gastric carcinoma: new developments in the field. Gastroenterology. 1995;90:2213-2216.
29. Forman D, Newell DG, Fullerton F, et al. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ. 1991;302:1302-1305.
30. Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991;325: 1127-1131.
31. Eslik G, Lim L, Byles J, et al. Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Am J Gastroenterol. 1999;94:2373-2379.
32. Werner M, Becker K, Keller G, al. e. Gastric adenocarcinoma: pathomorphology and molecular pathology. J Cancer Res Clin Oncol. 2001;127:207-216.
33. Fuchs CS, Mayer RJ. Gastric carcinoma. N Engl J Med. 1995;333:32-41.
34. Lauren T. The two histological main types of gastric carcinoma. Acta Pathol Microbiol Scand. 1965;64:34.
35. Goldgar DE, Easton DF, Cannon-Albright LA, et al. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst. 1994;86:1600-1608.
36. Livingston E. Stomach and duodenum. In: Norton J, Bollinger R, Chang A, et al., eds. Surgery. Basic Science and Clinical Evidence. New York: Springer-Verlag; 2001:489-515.
37. Albert C. Clinical Aspects of Gastric Cancer. Gastrointestinal Cancers: Biology, Diagnosis, and Therapy. Philadelphia: Lippincot-Raven; 1995:197-216.
38. Sadowski DC, Rabeneck L. Gastric ulcers at endoscopy: brush, biopsy, or both? Am J Gastroenterol. 1997;92:608-613.
39. Willis S, Truong S, Gribnitz S, et al. Endoscopic ultrasonography in the preoperative staging of gastric cancer: accuracy and impact on surgical therapy. Surg Endosc. 2000;14:951-954.
40. Halvorsen RA Jr, Yee J, McCormick VD. Diagnosis and staging of gastric cancer. Semin Oncol. 1996;23:325-335.
41. Kuntz C, Herfarth C. Imaging diagnosis for staging of gastric cancer. Semin Surg Oncol. 1999;17:96-102.
42. Monig SP, Zirbes TK, Schroder W, et al. Staging of gastric cancer, correlation of lymph node size and metastatic infiltration. AJR Am J Roentgenol. 1999;173:365-367.
43. Angelelli G, Ianora AA, Scardapane A, et al. Role of computerized tomography in the staging of gastrointestinal neoplasms. Semin Surg Oncol. 2001;20:109-121.
44. Sohn K, Lee J, Lee S, et al. Comparing MR Imaging and CT in the staging of gastric carcinoma. AJR Am J Roentgenol. 2000;174:1551-1557.
45. Motohara T, Semelka RC. MRI in staging of gastric cancer. Abdom Imaging. 2002;27:376-383.
46. Kim AY, Han JK, Seong CK, et al. MRI in staging advanced gastric cancer: is it useful compared with spiral CT? J Comput Assist Tomogr. 2000;24:389-394.
47. Bozzetti F, Bonfanti G, Bufalino R, et al. Adequacy of margins of resection in gastrectomy for cancer. Ann Surg. 1982;196:685-690.
48. Bozzetti F. Principles of surgical radicality in the treatment of gastric cancer. Surg Oncol Clin North Am. 2001;10:833-854, ix.
49. Pierie J, Ott M. Gastric cancer. In: Cameron J, ed. Current Surgical Therapy, 7th ed. St. Louis: Mosby; 2001:105-112.
50. Harrison LE, Karpeh MS, Brennan MF. Total gastrectomy is not necessary for proximal gastric cancer. Surgery. 1998;123:127-130.
51. Diaz De Liano A, Oteiza Martinez F, Ciga MA, et al. Impact of surgical procedure for gastric cancer on quality of life. Br J Surg. 2003;90:91-94.
52. Braga M, Molinari M, Zuliani W, et al. Surgical treatment of gastric adenocarcinoma: impact on survival and quality of life. A prospective ten year study. Hepatogastroenterology. 1996;43:187-193.
53. Buhl K, Schlag P, Herfarth C. Quality of life and functional results following different types of resection for gastric carcinoma. Eur J Surg Oncol. 1990;16:404-409.
54. Heberer G, Teichmann RK, Kramling HJ, et al. Results of gastric resection for carcinoma of the stomach: the European experience. World J Surg. 1988;12:374-381.
55. Onate-Ocana LF, Aiello-Crocifoglio V, Mondragon-Sanchez R, et al. Survival benefit of D2 lymphadenectomy in patients with gastric adenocarcinoma. Ann Surg Oncol. 2000;7:210-217.
56. Otsuji E, Toma A, Kobayashi S, et al. Outcome of prophylactic radical lymphadenectomy with gastrectomy in patients with early gastric carcinoma without lymph node metastasis. Cancer. 2000;89:1425-1430.
57. Shimada S, Yagi Y, Honmyo U, et al. Involvement of three or more lymph nodes predicts poor prognosis in submucosal gastric carcinoma. Gastric Cancer. 2001;4:54-59.
58. Maruyama K, Okabayashi K, Kinoshita T. Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg. 1987;11: 418-425.
59. Nakamura K, Ueyama T, Yao T, et al. Pathology and prognosis of gastric carcinoma. Findings in 10,000 patients who underwent primary gastrectomy. Cancer. 1992;70:1030-1037.
60. Wanebo HJ, Kennedy BJ, Chmiel J, et al. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg. 1993;218:583-592.
61. Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. Dutch Gastric Cancer Group. N Engl J Med. 1999;340:908-914.
62. Siewert JR, Bottcher K, Stein HJ, et al. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg. 1998;228:449-461.
63. Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer. 1999;79:1522-1530.
64. Baba H, Maehara Y, Takeuchi H, et al. Effect of lymph node dissection on the prognosis in patients with node-negative early gastric cancer. Surgery. 1995;117:165-169.
65. Otsuji E, Toma A, Kobayashi S, et al. Long-term benefit of extended lymphadenectomy with gastrectomy in distally located early gastric carcinoma. Am J Surg. 2000;180:127-132.
66. Marubini E, Bozzetti F, Miceli R, et al. Lymphadenectomy in gastric cancer: prognostic role and therapeutic implications. Eur J Surg Oncol. 2002;28:406-412.
67. Takeuchi K, Tsuzuki Y, Ando T, et al. Total gastrectomy with distal pancreatectomy and splenectomy for advanced gastric cancer. J Surg Res. 2001;101:196-201.
68. Volpe CM, Driscoll DL, Douglass HO Jr. Outcome of patients with proximal gastric cancer depends on extent of resection and number of resected lymph nodes. Ann Surg Oncol. 2000;7:139-144.
69. Roukos DH. Extended (D2) lymph node dissection for gastric cancer: do patients benefit? Ann Surg Oncol. 2000;7:253-255.
70. Roviello F, Marrelli D, Morgagni P, et al. Survival benefit of extended D2 lymphadenectomy in gastric cancer with involvement of second level lymph nodes: a longitudinal multicenter study. Ann Surg Oncol. 2002;9:894-900.
71. Ramacciato G, Aurello P, D'Angelo F, et al. Does extended lymphadenectomy influence prognosis of gastric carcinoma after curative resection? Hepatogastroenterology. 2000;47:1470-1474.
72. Maehara Y, Kakeji Y, Koga T, et al. Therapeutic value of lymph node dissection and the clinical outcome for patients with gastric cancer. Surgery. 2002;131(suppl):S85-91.
73. Kim JP. Current status of surgical treatment of gastric cancer. J Surg Oncol. 2002;79:79-80.
74. Kodera Y, Schwarz RE, Nakao A. Extended lymph node dissection in gastric carcinoma: where do we stand after the Dutch and British Randomized Trials? J Am Coll Surg. 2000;195:855-864.
75. Karpeh MS, Leon L, Klimstra D, et al. Lymph node staging in gastric cancer: is location more important than number? An analysis of 1,038 patients. Ann Surg. 2000;232:362-371.
76. Mullaney PJ, Wadley MS, Hyde C, et al. Appraisal of compliance with the UICC/AJCC staging system in the staging of gastric cancer. Union International Contra la Cancrum/American Joint Committee on Cancer. Br J Surg. 2002;89:1405-1408.
77. Kodera Y, Yamamura Y, Shimizu Y, et al. The number of metastatic lymph nodes: a promising prognostic determinant for gastric carcinoma in the latest edition of the TNM classification. J Am Coll Surg. 1998;187:597-603.
78. Ichikura T, Ogawa T, Chochi K, et al. Minimum number of lymph nodes that should be examined for the International Union Against Cancer/American Joint Committee on Cancer TNM classification of gastric carcinoma. World J Surg. 2003;27:330-333.
79. Middleton G, Cunningham D. Current options in the management of gastrointestinal cancer. Ann Oncol. 1995;6(suppl 1):17-25: discussion 25-26.
80. Theuer CP, Kurosaki T, Ziogas A, et al. Asian patients with gastric carcinoma in the United States exhibit unique clinical features and superior overall and cancer specific survival rates. Cancer. 2000;89: 1883-1892.
81. Schlemper RJ, Itabashi M, Kato Y, et al. Differences in diagnostic criteria for gastric carcinoma between Japanese and Western pathologists. Lancet. 1997;349:1725-1729.
82. Hermans J, Bonenkamp JJ, Boon MC, et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol. 1993;11:1441-1447.
83. Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer. 1999;35:1059-1064.
84. Mari E, Floriani I, Tinazzi A, et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparate Digerente). Ann Oncol. 2000;11: 837-843.
85. Janunger KG, Hafstrom L, Nygren P, et al. A systematic overview of chemotherapy effects in gastric cancer. Acta Oncol. 2001;40:309-326.
86. Gianni L, Panzini I, Tassinari D, et al. Meta-analyses of randomized trials of adjuvant chemotherapy in gastric cancer. Ann Oncol. 2001;12: 1178-1180.
87. Hu JK, Chen ZX, Zhou ZG, et al. Intravenous chemotherapy for resected gastric cancer: meta-analysis of randomized controlled trials. World J Gastroenterol. 2002;8:1023-1028.
88. Janunger KG, Hafstrom L, Glimelius B. Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg. 2002;168: 597-608.
89. Agboola O. Adjuvant treatment in gastric cancer. Cancer Treat Rev. 1994;20:217-240.
90. Yonemura Y, Sawa T, Kinoshita K, et al. Neoadjuvant chemotherapy for high-grade advanced gastric cancer. World J Surg. 1993;17:256-261; discussion 261-262.
91. Songun I, Keizer HJ, Hermans J, et al. Chemotherapy for operable gastric cancer: results of the Dutch randomised FAMTX trial. The Dutch Gastric Cancer Group (DGCG). Eur J Cancer. 1999;35;558-562.
92. Earle CC, Maroun J, Zuraw L. Neoadjuvant or adjuvant therapy for resectable gastric cancer? A practice guideline. Can J Surg. 2002;45: 438-446.
93. Dent DM, Werner ID, Novis B, et al. Prospective randomized trial of combined oncological therapy for gastric carcinoma. Cancer. 1979;44: 385-391.
94. Moertel CG, Childs DS, O'Fallon JR, et al. Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma. J Clin Oncol. 1984;2:1249-1254.
95. Kelsen DP. Postoperative adjuvant chemoradiation therapy for patients with resected gastric cancer: intergroup 116. J Clin Oncol. 2000; 18(suppl):32S-34S.
96. Thompson GB, van Heerden JA, Sarr MG. Adenocarcinoma of the stomach: are we making progress? Lancet. 1993;342:713-718.
97. Glimelius B, Ekstrom K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997;8:163-168.
98. Murad AM, Santiago FF, Petroianu A, et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 1993;72:37-41.
99. Pyrhonen S, Kuitunen T, Nyandoto P, et al. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995;71:587-591.
100. Schipper DL, Wagener DJ. Chemotherapy of gastric cancer. Anticancer Drugs. 1996;7:137-149.
101. Wils J. Treatment of gastric cancer. Curr Opin Oncol. 1998;10;357-361.
102. Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997;15:261-267.
103. Vanhoefer U, Rougier P, Wilke H, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol. 2000; 18:2648-2657.
104. Roder JD, Bottcher K, Busch R, et al. Classification of regional lymph node metastasis from gastric carcinoma. German Gastric Cancer Study Group. Cancer. 1998;82:621-631.
105. Yokota T, Kunii Y, Teshima S, et al. Significant prognostic factors in patients with early gastric cancer. Int Surg. 2000;85:286-290.
106. Adachi Y, Shiraishi N, Suematsu T, et al. Most important lymph node information in gastric cancer: multivariate prognostic study. Ann Surg Oncol. 2000;7:503-507.
107. Takahashi I, Matsusaka T, Onohara T, et al. Clinicopathological features of long-term survivors of scirrhous gastric cancer. Hepatogastroenterology. 2000;47:1485-1488.
108. Kim TH, Han SU, Cho YK, et al. Perigastric lymph node status can be a simple prognostic parameter in patients with gastric cancer. Hepatogastroenterology. 2000;47:1475-1478.
109. Kikuchi S, Sato M, Katada N, et al. Surgical outcome of node-positive early gastric cancer with particular reference to nodal status. Anticancer Res. 2000;20:3695-3700.
110. Yokota T, Kunii Y, Teshima S, et al. Significant prognostic factors in patients with node-negative gastric cancer. Int Surg. 1999;84:331-336.
111. Pinto-de-sousa J, David L, Seixas M, et al. Clinicopathologic profiles and prognosis of gastric carcinoma from the cardia, fundus/body and antrum. Dig Surg. 2001;18:102-110.
112. Hyung WJ, Lee JH, Choi SH, et al. Prognostic impact of lymphatic and/or blood vessel invasion in patients with node-negative advanced gastric cancer. Ann Surg Oncol. 2002;9:562-567.
113. Kooby DA, Suriawinata A, Klimstra DS, et al. Biologic predictors of survival in node-negative gastric cancer. Ann Surg. 2003;237:828-835; discussion 835-837.
114. Medina-Franco H, Heslin MS, Certes-Gonzalez R. Clinicopathological characteristics of gastric carcinoma in young and elderly patients: a comparative study. Ann Surg Oncol. 2000;7:515-519.
115. Caspar MJ, Arribas I, Coca MC, et al. Prognostic value of carcinoembryonic antigen, CA 19-9 and CA 72-4 in gastric carcinoma. Tumour Biol. 2001;22:318-322.
116. Allgayer H, Babic R, Gruetzner KU, et al. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol. 2000; 18:2201-2209.
117. Starzynska T, Markiewski M, Domagala W, et al. The clinical significance of p53 accumulation in gastric carcinoma. Cancer. 1996;77: 2005-2012.
118. Fletcher R, Fletcher S, Wagner E. Prognosis. In: Satterfield T, ed. Clinical Epidemiology. The Essentials, 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 1996:111-135.
119. Saunders L, Hayward R, Fischer B. Critical appraisal of the health sciences literature. In: Guyatt G, Rennie D, eds. Users' Guides to the Medical Literature. Chicago: AMA Press; 2002:141-153.
120. Becker KF, Keller G, Hoefler H. The use of molecular biology in diagnosis and prognosis of gastric cancer. Surg Oncol. 2000;9:5-11.
121. Boussioutas A, Taupin D. Towards a molecular approach to gastric cancer management. Intern Med J. 2001;31:296-303.
122. Ramaswamy S, Golub TR. DNA microarrays in clinical oncology. J Clin Oncol. 2002;20:1932-1941.
123. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100: 57-70.
124. Lee S, Baek M, Yang H, et al. Identification of genes differentially expressed between gastric cancers and normal gastric mucosa with cDNA microarrays. Cancer Lett. 2002;184:197-206.
125. Yasui W, Oue N, Kuniyasu H, et al. Molecular diagnosis of gastric cancer: present and future. Gastric Cancer. 2001;4:113-121.
126. Lockhart DJ, Winzeler EA. Genomics, gene expression and DNA arrays. Nature. 2000;405:827-836.
127. King HC, Sinha AA. Gene expression profile analysis by DNA microarrays: promise and pitfalls. JAMA. 2001;286:2280-2288.
128. Schadt EE, Li C, Su C, et al. Analyzing high-density oligonucleotide gene expression array data. J Cell Biochem. 2000;80:192-202.
129. Raetz EA, Moos PJ, Szabo A, et al. Gene expression profiling. Methods and clinical applications in oncology. Hematol Oncol Clin North Am. 2001;15:911-930, ix.
130. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999-2009.
131. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869-10874.
132. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415: 530-536.
133. Wigle DA, Jurisica I, Radulovich N, et al. Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Res. 2002;62:3005-3008.
134. Iizuka N, Oka M, Yamada-Okabe H, et al. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet. 2003;361:923-929.
135. Selaru FM, Zou T, Xu Y, et al. Global gene expression profiling in Barrett's esophagus and esophageal cancer: a comparative analysis using cDNA microarrays. Oncogene. 2002;21:475-478.
136. Ji J, Chen X, Leung SY, et al. Comprehensive analysis of the gene expression profiles in human gastric cancer cell lines. Oncogene. 2002;21:6549-6556.
137. Hippo Y, Taniguchi H, Tsutsumi S, et al. Global gene expression analysis of gastric cancer by oligonucleotide microarrays. Cancer Res. 2002;62:233-240.
138. Hippo Y, Yashiro M, Ishii M, et al. Differential gene expression profiles of scirrhous gastric cancer cells with high metastatic potential to peritoneum or lymph nodes. Cancer Res. 2001;61:889-895.
139. Meireles SI, Carvalho AF, Hirata R, et al. Differentially expressed genes in gastric tumors identified by cDNA array. Cancer Lett. 2003; 190:199-211.
140. El-Rifai W, Frierson H, Harper JC, et al. Expression profiling of gastric adenocarcinoma using cDNA array. Int J Cancer. 2001;93:832-838.
141. Liu LX, Liu ZH, Jiang HC, et al. Profiling of differentially expressed genes in human gastric carcinoma by cDNA expression array. World J Gastroenterol. 2002;8:580-585.
142. Inoue H, Matsuyama A, Mimori K, et al. Prognostic score of gastric cancer determined by cDNA microarray. Clin Cancer Res. 2002;8: 3475-3479.
143. Hasegawa S, Furukawa Y, Li M, et al. Genome-wide analysis of gene expression in intestinal-type gastric cancers using a complementary DNA microarray representing 23,040 genes. Cancer Res. 2002;62: 7012-7017.